We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GLIBK:NASDAQGCI Liberty, Inc. - Series C GCI Group Analysis

Data as of 2026-04-06 - not real-time

$37.02

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

GCI Liberty (GLIBK) is trading at $37.02, just below the calculated resistance of $37.96 and modestly above the 20‑day SMA ($36.76) while still under the 50‑day SMA ($37.79), indicating a neutral price trend. Technical momentum is slightly bullish, with the MACD line crossing above its signal and a positive histogram, and the RSI sits near the midpoint at 48.7, suggesting no immediate overbought pressure.
Fundamentally, the stock appears undervalued – the price‑to‑book ratio of 0.87 and a DCF‑derived fair value of $39.95 imply a discount to intrinsic value. However, profitability is weak, with a trailing EPS of –$9.97, a negative net profit margin (‑29.5%), and a negative ROE (‑19.7%). The company generates solid operating cash flow ($370 M) and free cash flow ($170 M), but carries a high debt load ($1.12 B) and a debt‑to‑equity ratio of 65.8, offset by $416 M in cash. Volatility is elevated at 23% over the past 30 days, though beta is low (0.51), and market sentiment is in “Extreme Greed” mode (78.8 on the Fear & Greed Index). Recent news is limited to routine corporate communications (2026 virtual annual meeting) and a mention of a 2025 stock surge, offering little substantive catalyst.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price near resistance with neutral trend
  • Bullish MACD signal but weak earnings
  • Stable volume and low beta mitigate short‑term downside

Medium Term

1–3 years
Positive
Model confidence: 6/10

Key Factors

  • Discount to book value and DCF fair value
  • Positive operating cash flow despite net loss
  • Potential upside if earnings turnaround occurs

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • High debt burden may limit growth
  • No dividend and negative EPS reduce income appeal
  • Valuation cushion from low price‑to‑book offers downside protection

Key Metrics & Analysis

Financial Health

Revenue Growth-0.40%
Profit Margin-29.54%
ROE-19.71%
ROA3.36%
Debt/Equity65.83
P/B Ratio0.9
Op. Cash Flow$370.0M
Free Cash Flow$170.1M
Industry P/E17.3

Technical Analysis

TrendNeutral
RSI48.7
Support$35.13
Resistance$37.96
MA 20$36.76
MA 50$37.79
MA 200$36.07
MACDBullish
VolumeStable
Fear & Greed Index78.8

Valuation

Fair Value$39.95
GradeUndervalued
TypeValue

Risk Assessment

Beta0.51
Volatility23.15%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.